Gennadiy, Trustee for TreatSMA, secures position on Spinraza advisory panel

Our Trustee Gennadiy Ilyashenko has been accepted as a patient organisation representative on the Spinraza managed access oversight committee. This is fantastic news.

Approving a medication like Spinraza TM is a complex process which has many uncertainties. Successful implementation and review of the treatment is of paramount importance to all stakeholders. Therefore as part of the Managed Access Agreement a panel of specialist and patient representatives has been formed to oversee the whole process, raise issues and offer solutions to ensure a fair and wide access to the treatment. This panel will also offer advice to clinicians and be a location that people can go to for 2nd opinions regarding treatment.

“As a part of this appointment TreatSMA will continue to advocate for all and do everything possible to ensure that our treatment for all goal achieved swiftly.” Commented Gennadiy on hearing the news.

This is great news for TreatSMA as we will be at the forefront of decision-making, as well as the community as a whole who now have a voice in a very important forum.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more